22 completed, 10 recruiting, 8 unknown, 6 not yet recruiting. 54 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 54 | Completed 22, Recruiting 10, Unknown 8, Not yet recruiting 6, Active not recruiting 3, Withdrawn 3, Terminated 2 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | 400 | 2027-03-01 | 2026-03-16 |
| Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting. - Multiple Myeloma in Relapse | Phase 4 | Not yet recruiting | Odense University Hospital | 50 | 2026-11-01 | 2026-10-21 |
| A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments Elranatamab - Relapsed/Refractory Multiple Myeloma, Multiple Myeloma | Phase 4 | Not yet recruiting | Pfizer | 75 | 2026-10-22 | 2026-10-19 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| Isa-VRD in TIE HRMM Isatuximab, bortezomib, lenalidomide, dexamethason, Bortezomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 117 | 2026-01-30 | 2026-01-13 |
| Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L - Multiple Myeloma Refractory, Relapsed Multiple Myeloma | Phase 4 | Recruiting | CHU de Quebec-Universite Laval | 80 | 2026-01-05 | 2026-07-22 |
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| Bioequivalence Studies of Dasatinib 100 Mg Dasatinib 100 MG - Myeloma Multiple | Phase 4 | Not yet recruiting | Centro de Atencion e Investigacion Medica | 46 | 2025-09-01 | 2025-02-12 |
| Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone - Peripheral Neuropathy, Multiple Myeloma, Neoplasms | Phase 4 | Recruiting | Tanta University | 44 | 2025-08-30 | 2025-11-04 |
| A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma Teclistamab - Multiple Myeloma | Phase 4 | Active not recruiting | Johnson & Johnson Private Limited | 75 | 2025-05-22 | 2026-11-03 |
| Plan Development for Giving Teclistamab in the Outpatient Setting Teclistamab, Tocilizumab - Multiple Myeloma, Relapsed Cancer | Phase 4 | Recruiting | University Health Network, Toronto | 15 | 2024-11-19 | 2025-12-10 |
| Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection Carfilzomib, Daratumumab, Lenalidomide - Newly Diagnosed, High Risk | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 59 | 2024-06-12 | 2025-06-12 |
| A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation Pentaisomaltose - Malignant Lymphoma, Multiple Myeloma | Phase 4 | Unknown | Pharmacosmos A/S | 150 | 2024-04-30 | 2024-04-03 |
| Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma Aspirin, Rivaroxaban - Multiple Myeloma, Venous Thromboembolism (VTE) | Phase 4 | Recruiting | Chen Lijuan | 200 | 2024-02-01 | 2026-10-30 |
| Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) Elranatamab - Multiple Myeloma | Phase 4 | Recruiting | Pfizer | 80 | 2023-10-03 | 2026-07-01 |
| Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients Tocilizumab - Multiple Myeloma | Phase 4 | Unknown | The First Affiliated Hospital of Soochow University | 48 | 2023-04-17 | 2023-06-02 |
| Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study Pomalidomide 4 mg every day in cycle 1, Pomalidomide 4 mg every other day in cycle 2, Pomalidomide 2 mg every day in cycle 2 - Multiple Myeloma in Relapse, Multiple Myeloma | Phase 4 | Completed | Amsterdam UMC, location VUmc | 12 | 2022-12-01 | 2025-04-22 |
| Home Based Daratumumab Administration for Patients With Multiple Myeloma Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life Assessment - Plasma Cell Myeloma | Phase 4 | Completed | Thomas Jefferson University | 20 | 2022-11-08 | 2025-11-21 |
| Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma Ixazomib plus low-dose lenalidomide, Ixazomib - Multiple Myeloma | Phase 4 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2022-07-01 | 2026-01-05 |
| Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury HFR-SUPRA, hemodialysis, Chemotherapy - Multiple Myeloma, Acute Kidney Injury | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 50 | 2022-07-01 | 2022-06-23 |
Showing 20 of 54. Sign in to see all of them.
Neoplasms (3) · Recurrence (3) · Back Pain (2) · Bone Neoplasms (2) · Breast Neoplasms (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms, Plasma Cell (2) · Prostatic Neoplasms (2) · Venous Thromboembolism (2) · Waldenstrom Macroglobulinemia (2) · Acute Kidney Injury (1) · Anemia (1) · Blast Crisis (1)
Blood Protein Disorders (54) · Cardiovascular Diseases (54) · Hematologic Diseases (54) · Hemic and Lymphatic Diseases (54) · Hemorrhagic Disorders (54) · Hemostatic Disorders (54) · Immune System Diseases (54) · Immunoproliferative Disorders (54) · Lymphoproliferative Disorders (54) · Neoplasms by Histologic Type (54) · Paraproteinemias (54) · Vascular Diseases (54) · Neoplasms, Plasma Cell (52) · Neoplasms (51) · Pathological Conditions, Signs and Symptoms (8)
Dexamethasone (11) · Lenalidomide (10) · Bortezomib (9) · Zoledronic Acid (8) · Melphalan (4) · daratumumab (4) · ixazomib (4) · Cyclophosphamide (3) · Thalidomide (3) · tocilizumab (3) · Calcium Dobesilate (2) · Doxorubicin (2) · Filgrastim (2) · Kyphoplasty (2) · Prednisone (2)
Peking Union Medical College Hospital (4) · Novartis Pharmaceuticals (3) · The First Affiliated Hospital of Soochow University (3) · Johnson & Johnson Private Limited (2) · Novartis (2) · PETHEMA Foundation (2) · Pfizer (2) · Takeda (2) · Amgen (1) · Amsterdam UMC, location VUmc (1) · Anne Louise Tølbøll Sørensen (1) · Basque Health Service (1) · CASI Pharmaceuticals (China) Co., Ltd. (1) · CHU de Quebec-Universite Laval (1) · Centre Hospitalier Universitaire de Nice (1)
China (15) · United States (14) · Spain (5) · Canada (3) · India (3) · Taiwan (3) · Australia (2) · Denmark (2) · France (2) · Japan (2) · Netherlands (2) · Belarus (1) · Belgium (1) · Colombia (1) · Egypt (1)
Junling Zhuang, MD (2) · Adam R Binder, MD (1) · Anatoly Uss, MD/PhD (1) · Ashraf M Alaa, BSc of clinical pharmacy (1) · Barry R. Meisenberg, MD (1) · Christine Chen, Dr. (1) · Dr Vincent Laroche, MD,FRCPC (1)
PMID 19246088, PMID 21912321, PMID 22443312, PMID 23446769, PMID 26069291, PMID 26644410, PMID 32418789, PMID 34582035, PMID 37807952, PMID 38116642, PMID 40396505
2023 (2), 2014 (1), P30CA138292 (1)